Evangelos Giampazolias received his BSc in Chemistry (2009) and MSc in Clinical Biochemistry (2012) from the University of Athens in Greece. In 2012, he moved to Glasgow, UK, to carry out his PhD at the CRUK Beatson Institute under the supervision of Professor Stephen Tait. During his PhD, he discovered the pro-inflammatory signals that accompany caspase-independent cell death and their impact on cancer immunity. For this, he was awarded the Institute of Cancer Sciences Prize (2017) and the CRUK Pontecorvo Prize (2018). Evangelos subsequently joined the group of Professor Caetano Reis e Sousa at the Francis Crick Institute in London, UK, as a Postdoctoral Fellow. There, he identified that the plasma actin-scavenging system promotes cancer immune escape by hijacking innate immune mechanisms of dead cell sensing in the tumour microenvironment. He was recently granted an innovation patent (2020) to explore the therapeutic potential of these findings as novel immunotherapies for cancers. His current work focuses on the identification of the mechanisms that permit the immune system to attack cancer through the detection of microbial signals from gut commensals.
In 2023, Evangelos will establish the Cancer Immunosurveillance group at the CRUK Manchester Institute, which will focus on the characterisation of the fundamental mechanisms that enable the immune system to recognise and respond to cancer through sensing and integration of cues that are elicited by dying cells and commensal microbes.